Rep. C. Scott Franklin Buys Shares of Novo Nordisk A/S (NYSE:NVO)

Posted by Francis Steltz on Sep 19th, 2026

Representative C. Scott Franklin (Republican-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 17th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 26th. The trade occurred in the Representative’s “FIDELITY ROTH IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 8/26/2026.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 8/20/2026.
Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 8/20/2026.
Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 8/20/2026.

Novo Nordisk A/S Stock Up 0.1%

NVO stock opened at $43.23 on Friday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The business’s 50-day moving average is $46.84 and its two-hundred day moving average is $43.81. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market cap of $193.04 billion, a price-to-earnings ratio of 10.57, a P/E/G ratio of 1.42 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.The business had revenue of $11.98 billion during the quarter. As a group, analysts forecast that Novo Nordisk A/S will post 3.53 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 20.05%.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently modified their holdings of NVO. Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after buying an additional 717,719 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of Novo Nordisk A/S in the first quarter worth about $287,660,000. Royal Bank of Canada boosted its stake in shares of Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after acquiring an additional 141,376 shares during the period. Renaissance Technologies LLC grew its position in shares of Novo Nordisk A/S by 6.7% during the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares in the last quarter. Finally, Markel Group Inc. raised its stake in Novo Nordisk A/S by 21.2% during the 4th quarter. Markel Group Inc. now owns 2,869,774 shares of the company’s stock valued at $146,014,000 after purchasing an additional 501,125 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: European regulators issued positive recommendations for Novo’s hemophilia A therapy FREHEMGO (denecimig), supporting a potential 2026 launch and providing a new rare-disease revenue opportunity. EMA panel backs Novo Nordisk haemophilia A drug FREHEMGO
Positive Sentiment: Sogroya received an important European recommendation for treating children with idiopathic short stature. Clinical data showed weekly treatment performed comparably with daily growth-hormone therapy, expanding the drug’s potential market. Sogroya wins EU recommendation
Positive Sentiment: Novo agreed to collaborate with Orbis Medicines on oral cardiometabolic drugs in a deal worth up to $1.4 billion. The partnership could help Novo develop oral alternatives to injectable therapies and diversify its obesity and diabetes pipeline. Novo and Orbis sign oral-drug deal
Positive Sentiment: An expanded partnership with Anthropic will use artificial intelligence to accelerate drug discovery and development. Investors view the initiative as a potential way to improve research productivity, though financial benefits are longer term. Novo expands AI push with Anthropic
Positive Sentiment: Novo confirmed stable Ozempic supply in Canada amid elevated semaglutide demand, reducing near-term availability concerns in an important market. Novo confirms stable Ozempic supply in Canada
Negative Sentiment: Novo halted two additional ziltivekimab cardiovascular trials after a late-stage study failed to reduce major adverse cardiovascular events. The setback weighs on efforts to diversify beyond the company’s core GLP-1 franchise. Novo halts two heart-drug trials
Negative Sentiment: Analysts continue to cite intensifying competition from Eli Lilly, semaglutide-related risks and recent share-price weakness. The Anthropic deal also has no disclosed financial terms or productivity targets, limiting its immediate earnings impact. Novo stock outlook amid competition

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NVO. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $64.94.

Check Out Our Latest Stock Analysis on NVO

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.